




# PREVENTIVE VETERINARY MEDICINE

An International Journal reporting on Methodological and Applied Research in Veterinary Epidemiology, Animal Disease Prevention & Control and Animal Health Economics, and on the contributions of Veterinary Epidemiology to One Health, including Environmental Health

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

●	<b>Description</b>	<b>p.1</b>
●	<b>Audience</b>	<b>p.1</b>
●	<b>Impact Factor</b>	<b>p.2</b>
●	<b>Abstracting and Indexing</b>	<b>p.2</b>
●	<b>Editorial Board</b>	<b>p.2</b>
●	<b>Guide for Authors</b>	<b>p.4</b>



ISSN: 0167-5877

### DESCRIPTION

*Preventive Veterinary Medicine* is one of the leading international resources for scientific reports on animal health programs and preventive veterinary medicine. The journal follows the guidelines for standardizing and strengthening the reporting of biomedical research which are available from the CONSORT, MOOSE, PRISMA, REFLECT, STARD, and STROBE statements. The journal focuses on: Epidemiology of health events relevant to domestic and wild animals; Economic impacts of epidemic and endemic animal and zoonotic diseases; Latest methods and approaches in veterinary epidemiology; Disease and infection control or eradication measures; The "One Health" concept and the relationships between veterinary medicine, human health, animal-production systems, and the environment; Development of new techniques in surveillance systems and diagnosis; Evaluation and control of diseases in animal populations. The journal encourages the submission of clinical and field-trial studies, particularly those related to new vaccines and other preventive measures. These studies, however, should follow the Consort Statement (<http://www.consort-statement.org>) or Reflect Statement (<http://reflect-statement.org>).

Prevalence studies may be considered for publication, but only if the results are likely to be of international interest (i.e. it must be possible to generalize the findings using scientifically based approaches). For these studies, key considerations in the review process will include (but are not limited to): consideration of both animal-level and herd-level demographics in the sampling design; the study population's relevance to the authors' described target population; the potential for confounding; and how well the sample-size justification assures high precision. The sensitivity and specificity of non-perfect tests used must be declared; the true rather than the apparent prevalence must be presented.

Submissions of reviews of relevant topics are also encouraged, but these should follow the systematic-review process addressed by the guidelines in the following two websites: <http://jama.ama-assn.org/cgi/reprint/283/15/2008>; <http://prisma-statement.org>.

*Preventive Veterinary Medicine* does not publish studies on experimental development of diagnostic assays without the appropriate field evaluation. Guidelines for the evaluation of diagnostic assays are followed in the review process (<http://www.stard-statement.org>).

### AUDIENCE

Research Workers in veterinary epidemiology and animal health.

## IMPACT FACTOR

---

2019: 2.304 © Clarivate Analytics Journal Citation Reports 2020

## ABSTRACTING AND INDEXING

---

AGRICOLA

Index Veterinarius

PubMed/Medline

BIOSIS Citation Index

Current Contents - Agriculture, Biology & Environmental Sciences

Review of Medical and Veterinary Entomology

Veterinary Bulletin

Scopus

## EDITORIAL BOARD

---

### *Co Editors-in-Chief*

**Marcus Doherr**, Free University of Berlin, Berlin, Germany

**Geoffrey Fosgate**, University of Pretoria, Pretoria, South Africa

**Polychronis Kostoulas**, University of Thessaly Faculty of Veterinary Science, Karditsa, Greece

### *Associate Editors*

**C.M. Budke**, College Station, Texas, United States

**N. Dhand**, Sydney, New South Wales, Australia

**H.N. Erb**, Ithaca, New York, United States

**R. Ivanek**, Ithaca, New York, United States

**P. H. Kass**, Davis, California, United States

**H.W. Ploeger**, Utrecht, Netherlands

**E.A. Raizman**, Roma, Italy

**H.-H. Thulke**, Leipzig, Germany

**I. Vågsholm**, Uppsala, Sweden

### *Editorial Advisory Board*

**P. Alarcon**, Hatfield, United Kingdom

**L.I. Alban**, Aarhus, Denmark

**M. Amaku**, São Paulo, Brazil

**H.W. Barkema**, Calgary, AB, Canada

**J. Becker**, Sydney, NSW, Australia

**R.D. Berghaus**, Athens, Georgia, United States

**O. Berke**, Guelph, ON, Canada

**A. E. Boklund**, København, Denmark

**D. C. Brodbelt**, London, United Kingdom

**M. Bruce**, Murdoch, Australia

**A. Catley**, Boston, Massachusetts, United States

**F. J. Conraths**, Greifswald, Germany

**K Cummings**, Ithaca, New York, United States

**J. Dahl**, Ugerl?se, Denmark

**M.J. Denwood**, Frederiksberg, Denmark

**J. Dewulf**, Merelbeke, Belgium

**S. Durr**, Liebefeld, Switzerland

**A. Egenvall**, Uppsala, Sweden

**J. Ellis-Iversen**, Søborg, Denmark

**K. Frankena**, Wageningen, Netherlands

**M. Gharbi**, Sidi Thabet, Tunisia

**A. Hill**, Davis, California, United States

**D.F. Kelton**, Guelph, ON, Canada

**C. Lanzas**, Raleigh, North Carolina, United States

**A. Lindberg**, Uppsala, Sweden

**S.A. McEwen**, Guelph, ON, Canada

**G.E. Monti**, Valdivia, Chile

**S.J. More**, Dublin, Ireland

**S.S. Nielsen**, Taastrup, Denmark

**B. Norby**, East Lansing, MI, United States  
**A.M. O'Connor**, Ames, Iowa, United States  
**D.L. Pendell**, Manhattan, Kansas, United States  
**Z. Poljak**, Guelph, Ontario, Canada  
**J. Rushton**, Liverpool, United Kingdom  
**M. Sanderson**, Manhattan, KS, United States  
**M.R. Slater**, New York, MA, United States  
**R. L. Smith**, Urbana, Illinois, United States  
**K. Steneroden**, Fort Collins, Colorado, United States  
**M. Stevenson**, Melbourne, Victoria, Australia  
**A. K. Stout**, Ithaca, New York, United States  
**P. Thompson**, Pretoria, South Africa  
**J.A. Toribio**, Camden, New South Wales, Australia  
**J.-P. Vaillancourt**, Montreal, QC, Canada  
**A. Wiethoelter**, Melbourne, Victoria, Australia  
**J. Zinsstag**, Basel, Switzerland

## GUIDE FOR AUTHORS

---

**Preventive Veterinary Medicine's** Editors and reviewers use several published guidelines for reporting standards; **the websites are listed in the Appendix to this Guide for Authors.** Conformation to these reporting standards allows our Editors and reviewers to judge the quality and originality of your work; conformation also offers readers sufficient information to judge the relevance of your study to the readers' own situations. Omission of substantive items from relevant guidelines for reporting standards is sufficient reason to reject your manuscript. **Thus, we highly encourage you to review this Guide for Authors and the relevant suggested website for your study. You must append** (to your initial manuscript submission) **a copy of the relevant checklist(s)** from listed websites such as STARD or REFLECT but not our own Guide for Authors. On the checklist, indicate the items you consider to be addressed within your paper. It remains the responsibility of the reviewers and Editors to decide whether the manner in which you addressed the checklist items is adequate for publication in *Preventive Veterinary Medicine*.

**Types of contribution** Original research papers (Regular Papers) Review articles Short communications Letters to the Editor Commentary *Original research papers* should report the results of original research. The material should not have been previously published elsewhere, except in a preliminary form.

*Review articles* should cover subjects falling within the scope of the journal which are of active current interest.

A *Short Communication* is a concise but complete description of a limited investigation, which will not be included in a later paper. Short Communications should be as completely documented, both by reference to the literature and description of the experimental procedures employed, as a regular paper. They should not occupy more than 6 printed pages (about 12 manuscript pages, including figures, tables and references).

*Letters to the Editor* offering comment, or useful critique on material published in the journal are welcomed. The decision to publish submitted letters rests purely with the Editor-in-Chief. Any letter received, and approved for publication, will be sent to the Corresponding Author of the paper to which it refers for a response. Both letter and response (if received) will then be published together. It is hoped that the publication of such letters will permit an exchange of views which will be of benefit to both the journal and its readers.

A *Commentary paper* may include research, application, demonstration, and/or teaching components. It should not exceed 1,000 words (not counting references, tables, and figures). It should be supported with scientifically logical evidence, publications, and/or professional observations. It is the responsibility of the contributor(s) to ensure that the language of the submission is at a high-quality, professional level of English (or peer review may not be possible).

### BEFORE YOU BEGIN

#### **Ethics in publishing**

Please see our information pages on [Ethics in publishing](#) and [Ethical guidelines for journal publication](#).

#### **Ethics in Animal Experimentation**

Circumstances relating to animal experimentation must meet the International Guiding Principles for Biomedical Research Involving Animals as issued by the Council for the International Organizations of Medical Sciences. They are obtainable from: Executive Secretary C.I.O.M.S., c/o WHO, Via Appia, CH-1211 Geneva 27, Switzerland, or at the following URL: [http://www.cioms.ch/publications/guidelines/1985\\_texts\\_of\\_guidelines.htm](http://www.cioms.ch/publications/guidelines/1985_texts_of_guidelines.htm). Unnecessary cruelty in animal experimentation is not acceptable to the Editors of *Preventive Veterinary Medicine*.

#### **Declaration of interest**

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. [More information](#).

### **Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see '[Multiple, redundant or concurrent publication](#)' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service [Crossref Similarity Check](#).

#### *Preprints*

Please note that [preprints](#) can be shared anywhere at any time, in line with Elsevier's [sharing policy](#). Sharing your preprints e.g. on a preprint server will not count as prior publication (see '[Multiple, redundant or concurrent publication](#)' for more information).

### **Use of inclusive language**

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

### **Authorship**

All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

### **Changes to authorship**

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

### **Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. [Permission](#) of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has [preprinted forms](#) for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' ([more information](#)). Permitted third party reuse of gold open access articles is determined by the author's choice of [user license](#).

### **Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

#### *Elsevier supports responsible sharing*

Find out how you can [share your research](#) published in Elsevier journals.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

### **Open access**

Please visit our [Open Access page](#) for more information.

#### *Elsevier Researcher Academy*

[Researcher Academy](#) is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

### **Language (usage and editing services)**

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors whose native language is not English are strongly advised to have their manuscripts checked by an English-speaking colleague prior to submission. Alternatively they may wish to use the English Language Editing service available from [Elsevier's WebShop](#) or visit our [customer support](#) site for more information.

### **Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

#### *Submit your article*

Please submit your article via <https://www.editorialmanager.com/prevet/default.aspx>.

## **PREPARATION**

### **Peer review**

This journal operates a single anonymized review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. Editors are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups. [More information on types of peer review](#).

#### *Use of word processing software*

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns.

The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the [Guide to Publishing with Elsevier](#)). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Manuscripts should have **numbered lines**, with wide margins and **double spacing** throughout, i.e. also for abstracts, footnotes and references. **Every page of the manuscript, including the title page, references, tables, etc., should be numbered.** However, in the text no reference should be made to page numbers; if necessary one may refer to sections. Avoid excessive usage of italics to emphasize part of the text.

## Article structure

### *Subdivision - unnumbered sections*

Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply 'the text'.

### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

### *Material and methods*

Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

### *Results*

Results should be clear and concise.

### *Discussion*

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

### *Conclusions*

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

## Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

## Highlights

Highlights are optional yet highly encouraged for this journal, as they increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: [example Highlights](#).

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

### **Abstract**

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Your abstract should not be longer than 400 words.

### **Keywords**

Immediately after the abstract, provide a maximum of 6 keywords, using British spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

### **Abbreviations**

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

### **Acknowledgements**

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

### **Formatting of funding sources**

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### **Units**

Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

### **Nomenclature**

1. Authors and editors are, by general agreement, obliged to accept the rules governing biological nomenclature, as laid down in the International Code of Botanical Nomenclature, the International Code of Nomenclature of Bacteria, and the International Code of Zoological Nomenclature.
2. All biotica (crops, plants, insects, birds, mammals, etc.) should be identified by their scientific names when the English term is first used, with the exception of common domestic animals.
3. All biocides and other organic compounds must be identified by their Geneva names when first used in the text. Active ingredients of all formulations should be likewise identified.
4. For chemical nomenclature, the conventions of the International Union of Pure and Applied Chemistry and the official recommendations of the IUPAC–IUB Combined Commission on Biochemical Nomenclature should be followed.

### **Formulae**

1. Give the meaning of all symbols immediately after the equation in which they are first used.

2. For simple fractions use the solidus (/) instead of a horizontal line.
3. Equations should be numbered serially at the right-hand side in parentheses. In general only equations explicitly referred to in the text need be numbered.
4. The use of fractional powers instead of root signs is recommended. Powers of e are often more conveniently denoted by exp.
5. In chemical formulae, valence of ions should be given as, e.g. Ca<sup>2+</sup>, not as Ca<sup>++</sup>.
6. Isotope numbers should precede the symbols, e.g. <sup>18</sup>O.
7. The repeated writing of chemical formulae in the text is to be avoided where reasonably possible; instead, the name of the compound should be given in full. Exceptions may be made in the case of a very long name occurring very frequently or in the case of a compound being described as the end product of a gravimetric determination (e.g. phosphate as P<sub>2</sub>O<sub>5</sub>).

#### *Footnotes*

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

### **Artwork**

#### *Electronic artwork*

##### *General points*

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.
- Ensure that color images are accessible to all, including those with impaired color vision.

A detailed [guide on electronic artwork](#) is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

#### *Formats*

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

#### **Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

#### *Color artwork*

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) in addition to color reproduction in print. [Further information on the preparation of electronic artwork.](#)

### *Illustration services*

[Elsevier's Author Services](#) offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

### *Figure captions*

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

### **Tables**

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

### **References**

#### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

In the text refer to the author's name (without initial) and year of publication, followed – if necessary – by a short reference to appropriate pages. Examples: "Since Peterson (1988) has shown that..." "This is in agreement with results obtained later (Kramer, 1989, pp.12–16)".

If reference is made in the text to a publication written by more than two authors the name of the first author should be used followed by "et al.". This indication, however, should never be used in the list of references. In this list names of first author and co-authors should be mentioned.

References cited together in the text should be arranged chronologically. The list of references should be arranged alphabetically on authors' names, and chronologically per author. If an author's name in the list is also mentioned with co-authors the following order should be used: publications of the single author, arranged according publication dates – publications of the same author with one co-author – publications of the author with more than one co-author. Publications by the same author(s) in the same year should be listed as 1974a, 1974b, etc.

#### *Reference links*

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. *Journal of Geophysical Research*, <https://doi.org/10.1029/2001JB000884>. Please note the format of such citations should be in the same style as all other references in the paper.

#### *Web references*

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

### Data references

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

### References in a special issue

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

### Reference management software

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#). Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. [More information on how to remove field codes from different reference management software](#).

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/preventive-veterinary-medicine>

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

### Reference style

*Text:* All citations in the text should refer to:

1. *Single author:* the author's name (without initials, unless there is ambiguity) and the year of publication;
2. *Two authors:* both authors' names and the year of publication;
3. *Three or more authors:* first author's name followed by 'et al.' and the year of publication.

Citations may be made directly (or parenthetically). Groups of references can be listed either first alphabetically, then chronologically, or vice versa.

Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999)... Or, as demonstrated (Jones, 1999; Allan, 2000)... Kramer et al. (2010) have recently shown ...'

*List:* References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.

#### Examples:

Reference to a journal publication:

Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2010. The art of writing a scientific article. *J. Sci. Commun.* 163, 51–59. <https://doi.org/10.1016/j.Sc.2010.00372>.

Reference to a journal publication with an article number:

Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2018. The art of writing a scientific article. *Heliyon.* 19, e00205. <https://doi.org/10.1016/j.heliyon.2018.e00205>.

Reference to a book:

Strunk Jr, W., White, E.B., 2000. *The Elements of Style*, fourth ed. Longman, New York.

Reference to a chapter in an edited book:

Mettam, G.R., Adams, L.B., 2009. How to prepare an electronic version of your article, in: Jones, B.S., Smith, R.Z. (Eds.), *Introduction to the Electronic Age*. E-Publishing Inc., New York, pp. 281–304.

Reference to a website:

Cancer Research UK, 1975. Cancer statistics reports for the UK. <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/> (accessed 13 March 2003).

Reference to a dataset:

[dataset] Oguro, M., Imahiro, S., Saito, S., Nakashizuka, T., 2015. Mortality data for Japanese oak wilt disease and surrounding forest compositions. *Mendeley Data*, v1. <https://doi.org/10.17632/xwj98nb39r.1>.

### *Journal abbreviations source*

Journal names should be abbreviated according to the List of Title Word Abbreviations: <http://www.issn.org/services/online-services/access-to-the-ltwa/>. The correct abbreviation for this journal is: Prev. Vet. Med.

### **Data visualization**

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions [here](#) to find out about available data visualization options and how to include them with your article.

### **Supplementary material**

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

### **Research data**

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the [research data](#) page.

#### *Data linking*

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

#### *Mendeley Data*

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to *Mendeley Data*. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

### *Data statement*

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

### **Submission checklist**

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

#### **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Phone numbers

All necessary contents of the manuscript text have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
- References are in the correct format for this journal
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Web)
- Color figures are clearly marked as being intended for color reproduction on the Web (free of charge) and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white in print
- If only color on the Web is required, black-and-white versions of the figures are also supplied for printing purposes

For any further information please visit our customer support site at <https://service.elsevier.com>.

### **Appendix**

Authors: These minimum items of information are needed by our referees and Editors to evaluate your manuscript. Additional information may be appropriate, depending on your study design and objectives.

Excellent guidelines for standardizing and strengthening the reporting of biomedical research are available from the CONSORT, MOOSE, PRISMA, REFLECT, STARD, and STROBE-VET statements. We strongly urge you to consult these guidelines before submitting papers to **Preventive Veterinary Medicine**. The guidelines are freely available (with considerable elaborations and explanations) at the following websites:

<http://www.consort-statement.org> (for clinical trials; there are elaborations for abstracts, cluster designs, reporting of harms, herbal interventions, non-inferiority and equivalence studies, trials of non-pharmacologic interventions, and pragmatic trials)

<http://jama.ama-assn.org/cgi/reprint/283/15/2008> (for MOOSE: Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting, Donna F. Stroup et al.; published in J Am Med Assoc 2000; 283:2008-2012)

<http://prisma-statement.org> (for meta-analyses and systematic reviews)

<http://reflect-statement.org> (for clinical trials in livestock)

<http://www.stard-statement.org> (for evaluations of diagnostic tests)

<https://strobvet-statement.org/> (for observational studies; there is an elaboration for studies of genetic associations)

#### 1. For **ALL descriptive and comparative studies:**

##### a. **Source** of subjects

- b. **Eligibility** criteria
  - c. **Sample-size justification** appropriate for the study design and primary hypothesis. This should include details of adjustment for clustering (including the levels of **clustering**, the assumed cluster size, and either the **design effect** or the **intracluster correlation**) if clustering was present.
  - d. Methods by which the data were acquired
  - e. Diagnostic **sensitivity and specificity** of any tests used. (Analytic sensitivity and reproducibility might be appropriate alternatives for some studies.) Correction to the **true prevalence** is expected for e.g., seroprevalence studies.
  - f. Descriptions of the observed data (including measures of subject-level variation), stratified on the outcome implied by the primary hypothesis. These descriptions should include time, place, "demographics," and relevant management and health information.
  - g. Declaration of the **experimental unit**
  - h. Descriptions of the **formal random mechanism** (e.g., lottery or table of random numbers) and the list frame (enumerating every eligible subject and/or cluster) used at any step claimed to be "random"
  - i. Descriptions of the **pilot, repeatability, and validation testing of any questionnaire** used to acquire data for the study. Also needed are: the language of the survey instrument, the time it took to complete, how it was administered, the types of questions (e.g., closed, semi-closed, open), and the training of any persons administering the survey. Making a copy available to the review process is desirable (in English as well as the language of administration).
2. For **comparative studies** (including **both observational and intervention** studies):
- a. Numerical descriptions of **all tested risk factors** or pre-intervention characteristics of the subjects, **stratified** on the primary hypothesis/outcome of the study
  - b. Descriptions of how **blindness** was accomplished for all subjective evaluations
3. For **randomized controlled trials and other intervention studies**:
- a. **Approval** by your institution's **animal-welfare committee** and description of measures taken for rescue analgesia or rescue euthanasia.
  - b. Methods by which the owners of the animals gave **informed consent** for their animals to be in the trial
  - c. Methods used for **allocation concealment** after the animals were determined to be eligible for random assignment to the various experimental or control groups
  - d. **Description and justification of the "control" group's "treatment"** (e.g., standard therapy, placebo to mimic the delivery system in the absence of a standard therapy, or "do nothing" to mimic both the treatment and its delivery)
  - e. Methods used for **active monitoring for adverse effects** ("harms")
4. For **simulation studies and risk assessments**:
- a. Distinction between deterministic and stochastic processes
  - b. Descriptions of (and justifications for) all choices of **distributions and their parameter Values**
  - c. Description of numbers, training, experience, and representativeness of any **"experts"** used to provide opinions
  - d. Declaration of the **stakeholders** for any risk assessment
  - e. Distinction between assumptions, input data, calculations from intermediate steps in the modeling process, and model predictions
  - f. Descriptions of the assumed chance variation and assumed knowledge uncertainty in the inputs, and methods used to deal with those sources of total uncertainty
  - g. **Sensitivity analyses** of key assumptions and of the input variables that had the greatest uncertainty
  - h. Descriptions of the **variability in the "outputs"** from stochastic models
5. For **statistical-hypothesis tests**:
- a. Declarations of the unit of statistical analysis and of the dependent ("outcome") variable
  - b. **Alpha** and **tails**, and any methods used to adjust for multiple comparisons (to protect experiment-wise alpha from the problem of **multiplicity**)
  - c. **Methods used to adjust for clustering within the data**

- d. Methods used to determine that the **statistical assumptions were met** (e.g., that the data were Gaussian or that the odds ratio or hazards ratio was constant across the observed range of the risk factor)
- e. Methods used to look for **collinearities** or other interrelationships among the risk factors being tested
- f. Methods used to select or to retain risk factors within multivariable models (including the **test criterion**)
- g. Clear declaration of any variables "forced into" the model (not allowed to drop out; this implies a need to account for that factor) or offered to the model on a priori grounds despite any screening results (this implies that the factor was part of a major hypothesis)
- h. Description of the **goodness-of-fit** of any models
- i. How **missing data** were handled

## **AFTER ACCEPTANCE**

### **Online proof correction**

To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### **Offprints**

The corresponding author will, at no cost, receive a customized [Share Link](#) providing 50 days free access to the final published version of the article on [ScienceDirect](#). The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's [Author Services](#). Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

## **AUTHOR INQUIRIES**

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).

© Copyright 2018 Elsevier | <https://www.elsevier.com>